Skip to main content
Clinical Trials/NCT02299271
NCT02299271
Terminated
Phase 4

Fascia Iliaca Block for Post-Operative Pain Control After Total Hip Arthroplasty: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study

The Christ Hospital1 site in 1 country72 target enrollmentJune 2014

Overview

Phase
Phase 4
Intervention
Ropivacaine
Conditions
Osteoarthritis of the Hip
Sponsor
The Christ Hospital
Enrollment
72
Locations
1
Primary Endpoint
Opioid Consumption
Status
Terminated
Last Updated
9 years ago

Overview

Brief Summary

This study evaluates post-operative pain management and narcotic consumption in patients receiving a fascia iliaca block with local anesthetic versus patients receiving fascia iliaca block with saline for total hip arthroplasty.

Detailed Description

Although many improvements have been made in implant technology and surgical approaches for total hip arthroplasty, management of post-operative pain remains a major clinical issue. Inadequate pain control can lead to numerous unwanted side effects and limited physical function, especially in a older population. Most surgeons have adopted a multi-modality pain management approach using a variety of pharmaceuticals, including nerve block with local anesthetic. In the literature, there are a number of technical variations described for the fascia iliaca nerve block. At The Christ Hospital, Cincinnati, Ohio, anesthesiologists use a more proximal approach to the fasica iliaca block enabling a significantly easier cephalad spread of the local anesthetic into the pelvis targeting all three nerves; the femoral, lateral femoral cutaneous, and the obturator. This prospective, double-blinded, randomized, single-center study is designed to test the primary hypothesis that fascia iliaca block with a local anesthestic decreases narcotic consumption and provides improved pain control compared to placebo in the first 24 hours after surgery in patients undergoing total hip arthroplasty.

Registry
clinicaltrials.gov
Start Date
June 2014
End Date
December 2016
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Brian Vaughan

Brian Vaughan, MD

The Christ Hospital

Eligibility Criteria

Inclusion Criteria

  • anterior approach total hip arthroplasty (THA) for unilateral osteoarthritis
  • English-speaking
  • age 18 to 75 years
  • American Society of Anesthesiologists (ASA) physical status 1 to 3
  • BMI \< 40 kg/m2
  • Minimum weight of 50 kg.
  • No contraindications to study procedures

Exclusion Criteria

  • Hip revision surgery
  • Allergy to local anesthetics
  • Allergy to oxycontin
  • Allergy to pregabalin
  • Allergy to fentanyl
  • Allergy to midazolam
  • Allergy to hydromorphone
  • BMI \> 40 kg/m2
  • Chronic pre-operative opioid use

Arms & Interventions

ropivacaine block

Ropivacaine 0.375% as a one-time 60 milliliter injection.

Intervention: Ropivacaine

saline block

Sodium chloride 0.9% as a one-time 60 milliliter injection.

Intervention: Saline

Outcomes

Primary Outcomes

Opioid Consumption

Time Frame: 24 hours

Measured by IV narcotic consumption beginning in the post-operative care unit and continuing 24 hours on the post-operative floor.

Pain Control

Time Frame: 24 hours

Measured by NRS-11 beginning in post-operative care unit and continuing 24 hours on the post-operative floor.

Secondary Outcomes

  • Post-Operative Care Unit (PACU) Length of Stay(From 60 minutes to 6 hours)

Study Sites (1)

Loading locations...

Similar Trials